ATNM Actinium Pharmaceuticals, Inc. Stock Quote

ATNM [AMEX]

Index	-	P/E	-	EPS (ttm)	-2.59	Insider Own	1.55%	Shs Outstand	15.43M	Perf Week	-2.42%
Market Cap	106.88M	Forward P/E	-	EPS next Y	-1.42	Insider Trans	0.00%	Shs Float	13.38M	Perf Month	2.68%
Income	-20.40M	PEG	-	EPS next Q	-0.37	Inst Own	24.20%	Short Float	5.24%	Perf Quarter	-25.99%
Sales	-	P/S	-	EPS this Y	34.20%	Inst Trans	10.31%	Short Ratio	1.29	Perf Half Y	-7.89%
Book/sh	2.94	P/B	2.74	EPS next Y	23.70%	ROA	-64.60%	Target Price	-	Perf Year	12.74%
Cash/sh	3.63	P/C	2.22	EPS next 5Y	-	ROE	-78.00%	52W Range	4.71 - 19.47	Perf YTD	3.33%
Dividend	-	P/FCF	-	EPS past 5Y	30.50%	ROI	-	52W High	-58.60%	Beta	1.07
Dividend %	-	Quick Ratio	10.50	Sales past 5Y	-	Gross Margin	-	52W Low	71.13%	ATR	0.48
Employees	25	Current Ratio	10.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	37.53	Volatility	6.17% 6.07%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	70.40%	Profit Margin	-	Rel Volume	0.38	Prev Close	8.06
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	544.38K	Price	8.06
Recom	1.80	SMA20	-8.81%	SMA50	-10.74%	SMA200	-20.89%	Volume	208,864	Change	0.00%

Nov-05-20

Initiated

Alliance Global Partners

Buy

$25

Dec-06-17

Initiated

B. Riley FBR, Inc.

Buy

$2.75

Oct-23-17

Resumed

ROTH Capital

Buy

Sep-14-17

Initiated

Maxim Group

Buy

Aug-25-16

Initiated

ROTH Capital

Buy

Feb-29-16

Initiated

H.C. Wainwright

Buy

Oct-15-15

Initiated

FBR Capital

Outperform

$12

Oct-01-14

Initiated

MLV & Co

Buy

$16

Jul-22-14

Initiated

Canaccord Genuity

Buy

$16

Feb-11-21 07:15AM	Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation & Cellular Therapy Annual Meeting PR Newswire
Feb-10-21 07:15AM	Actinium Announces Participation in BIO CEO & Investor Digital Conference PR Newswire
Jan-20-21 07:00AM	Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference PR Newswire
Jan-13-21 07:00AM	Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies PR Newswire
Dec-29-20 08:30AM	Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trial PR Newswire -24.63%
Dec-23-20 05:45PM	Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know Zacks
Dec-17-20 05:45PM	Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know Zacks
Dec-09-20 05:45PM	Actinium Pharmaceuticals (ATNM) Gains As Market Dips: What You Should Know Zacks
08:00AM	Actinium Highlights Presence at Targeted Radiopharmaceuticals Summit PR Newswire
Dec-08-20 08:00AM	Actinium Reports 67 Percent Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH PR Newswire
Dec-07-20 08:30AM	Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 75% of Total Patient Enrollment at the 62nd American Society of Hematology Annual Meeting PR Newswire
08:15AM	Actinium Highlights Iomab-B Safety Data Presented at the 62nd American Society of Hematology Annual Meeting PR Newswire
07:00AM	Actinium Presents Interim Data from Actimab-A CLAG-M Phase 1 Combination Trial at the 62nd American Society of Hematology Annual Meeting PR Newswire
Dec-03-20 07:00AM	Actinium Highlights Clinical Data to be Presented at the Upcoming 62nd American Society of Hematology Annual Meeting PR Newswire
Dec-02-20 08:49PM	Is Actinium Pharmaceuticals (ATNM) A Good Stock To Buy Now? Insider Monkey
05:45PM	Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know Zacks
Dec-01-20 07:00AM	Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development PR Newswire -6.64%
Nov-23-20 07:00AM	Actinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted Conditioning Until 2037 and Recent EU Patent Activity PR Newswire
Nov-20-20 05:45PM	Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know Zacks
Nov-19-20 07:30AM	Actinium Strengthens Leadership Team with Appointment of Dr. Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical Affairs PR Newswire
Nov-16-20 07:00AM	Actinium to Participate in the Alliance Global Partners' Virtual Healthcare Symposium PR Newswire +5.25%
Nov-13-20 05:45PM	Actinium Pharmaceuticals (ATNM) Gains But Lags Market: What You Should Know Zacks
Nov-11-20 08:00AM	Actinium to Host KOL Call on November 11th Featuring Actimab-A AML Combination Trials PR Newswire
Nov-04-20 12:21PM	100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML PR Newswire +10.25%
12:13PM	Actinium Announces Two Oral Presentations Featuring Data and Findings from the Phase 3 SIERRA Trial of Iomab-B at the 62nd American Society of Hematology Annual Meeting PR Newswire
12:00PM	Actinium Announces Actimab-A Venetoclax First-in-Human Data Accepted for Poster Presentation at the 62nd American Society of Hematology Annual Meeting PR Newswire
Oct-29-20 11:30AM	Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year? Zacks
Oct-28-20 07:00AM	Actinium Pharmaceuticals, Inc. Provides Corporate Update and Year-End 2020 Outlook PR Newswire
Oct-22-20 05:45PM	Actinium Pharmaceuticals (ATNM) Gains But Lags Market: What You Should Know Zacks
Oct-21-20 08:04AM	The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings Benzinga +7.58%
07:00AM	Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy PR Newswire
Oct-14-20 07:00AM	Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform PR Newswire
Oct-09-20 06:37AM	We Think Actinium Pharmaceuticals (NYSEMKT:ATNM) Can Afford To Drive Business Growth Simply Wall St.
Oct-08-20 05:45PM	Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know Zacks
Oct-06-20 07:00AM	Actinium Pharmaceuticals, Inc. Announces Clinical Trial Site Expansion in its Multi-Center Phase 1/2 Actimab-A Venetoclax Combination Trial PR Newswire
Oct-02-20 05:45PM	Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know Zacks
Sep-23-20 07:00AM	Actinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in Relapsed/Refractory AML Patients PR Newswire -9.36%
Sep-14-20 07:00AM	Actinium Pharmaceuticals Announces Successful Completion of Planned Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed/Refractory AML at Medical College of Wisconsin PR Newswire +8.33%
Sep-10-20 07:00AM	Actinium Pharmaceuticals, Inc. to Present at the 22nd Annual H.C. Wainwright Global Investor Conference PR Newswire
Aug-31-20 06:05PM	LD Micro: 360 Companies Set to Present this Week ACCESSWIRE
Aug-28-20 11:30AM	Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year? Zacks
Aug-26-20 08:48AM	Is a Surprise Coming for Actinium Pharmaceuticals (ATNM) This Earnings Season? Zacks
Aug-12-20 11:30AM	Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year? Zacks
Aug-10-20 02:30PM	Actinium Pharmaceuticals, Inc. Announces Reverse Stock Split PR Newswire -8.28%
12:00PM	Actinium Pharmaceuticals (ATNM) is a Great Momentum Stock: Should You Buy? Zacks
Aug-04-20 05:45PM	Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know Zacks
Aug-03-20 11:54AM	Actinium (ATNM) to Report Q2 Earnings: What's in the Cards? Zacks
Jul-28-20 05:50PM	Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know Zacks
Jul-27-20 11:30AM	Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year? Zacks +10.92%
Jul-23-20 12:00PM	Actinium Pharmaceuticals (ATNM) is a Great Momentum Stock: Should You Buy? Zacks
Jul-21-20 08:57AM	Implied Volatility Surging for Actinium Pharmaceuticals (ATNM) Stock Options Zacks +16.30%
Jul-20-20 10:32AM	Actinium Pharmaceuticals, Inc. (ATNM) Shares March Higher, Can It Continue? Zacks +12.43%
Jul-15-20 07:03AM	Actinium Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Jul-09-20 11:30AM	Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year? Zacks
Jul-08-20 09:05AM	The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio Zacks
Jun-19-20 05:15PM	Actinium Pharmaceuticals, Inc. Announces Closing of $25.0 Million Public Offering PR Newswire
Jun-17-20 11:30AM	Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year? Zacks -14.61%
Jun-16-20 11:30PM	Actinium Pharmaceuticals, Inc. Announces Pricing of $25.0 Million Public Offering PR Newswire +9.47%
04:01PM	Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering PR Newswire
Jun-15-20 11:29PM	Is the Options Market Predicting a Spike in Actinium Pharmaceuticals (ATNM) Stock? Zacks -9.67%
Jun-12-20 08:43AM	How Actinium Pharmaceuticals (ATNM) Stock Stands Out in a Strong Industry Zacks +6.91%
Jun-09-20 08:47AM	Actinium Pharmaceuticals (ATNM) Jumps: Stock Rises 6.7% Zacks +39.81%
Jun-04-20 09:45PM	Hedge Funds Cautiously Watching Actinium Pharmaceuticals Inc (ATNM) Insider Monkey +30.98%
09:42AM	Benzinga's Top Upgrades, Downgrades For June 4, 2020 Benzinga
Jun-03-20 09:53AM	3 Strong Buy Healthcare Stocks Under $5 With Big Upside Potential TipRanks
Apr-24-20 05:15PM	Actinium Pharmaceuticals, Inc. Announces Closing of $31.6 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares PR Newswire
Apr-21-20 11:35PM	Actinium Pharmaceuticals, Inc. Announces Pricing of $27.5 Million Public Offering PR Newswire
04:01PM	Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering PR Newswire
Apr-16-20 07:00AM	Actinium Provides Update on Iomab-B SIERRA Trial and Expected Topline Results from Ad Hoc Analysis in 2020 PR Newswire
Apr-12-20 09:02AM	Can Actinium Pharmaceuticals (NYSEMKT:ATNM) Afford To Invest In Growth? Simply Wall St.
Mar-06-20 10:56AM	Actinium Treats First Patient in AML Study on Actimab-A Combo Zacks
Mar-05-20 07:30AM	Actinium Pharmaceuticals Announces First Patient Treated in Third and Final Dose Cohort of Actimab-A CLAG-M Combination Phase 1 Trial in Acute Myeloid Leukemia PR Newswire +16.43%
Feb-26-20 07:33AM	Actinium Announces Actimab-A Plus 7+3 Combination Trial for Newly Diagnosed Acute Myeloid Leukemia Patients PR Newswire
Feb-25-20 09:33AM	Actinium (ATNM) to Report Q4 Earnings: What's in the Cards? Zacks -6.08%
Feb-21-20 07:30AM	Actinium Presents Positive Findings from Mid-Point Analysis of Pivotal SIERRA Trial of Iomab-B at 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT) PR Newswire
Feb-13-20 08:03AM	Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting; Phase 3 SIERRA Trial Preliminary Results Selected for Oral Presentation PR Newswire
Feb-05-20 05:50PM	Actinium Pharmaceuticals (ATNM) Gains But Lags Market: What You Should Know Zacks
08:03AM	Actinium Pharmaceuticals, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference PR Newswire
Jan-30-20 05:45PM	Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know Zacks
Jan-13-20 12:00PM	Actinium (ATNM) Upgraded to Strong Buy: Here's Why Zacks +9.60%
07:15AM	One Thing To Remember About The Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) Share Price Simply Wall St.
07:03AM	Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma PR Newswire
Jan-07-20 07:03AM	Actinium Pharmaceuticals, Inc. to Present at 2020 Biotech Showcase PR Newswire
Jan-03-20 11:30AM	Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year? Zacks
Jan-02-20 09:29AM	Tilray (TLRY) in Focus: Stock Moves 9% Higher Zacks +9.14%
Dec-22-19 05:08PM	Hedge Funds Have Never Been More Bullish On Actinium Pharmaceuticals Inc (ATNM) Insider Monkey
Dec-09-19 06:10AM	Actinium Pharmaceuticals Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH 2019 Annual Meeting PR Newswire -9.56%
06:00AM	Actinium Pharmaceuticals Announces Phase 3 SIERRA Trial Dosimetry Results Support Low Dose Iomab-B for Targeted Lymphodepletion Prior to Adoptive Cell Therapy PR Newswire
Dec-07-19 08:35AM	The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling Benzinga
Dec-01-19 09:30AM	The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More Benzinga
Nov-20-19 09:00AM	What Makes Actinium (ATNM) a New Buy Stock Zacks
Nov-07-19 04:05PM	Actinium Pharmaceuticals to Present at the 25th Annual BIO-Europe® 2019 International Partnering Conference PR Newswire
Nov-06-19 09:15AM	Actinium Announces Interim Results from Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML Accepted for Presentation at ASH 2019 PR Newswire
09:00AM	Actinium Pharmaceuticals to Present New Clinical Findings from SIERRA Trial Supporting the Iomab-ACT Program for Targeted Lymphodepletion for CAR-T and Adoptive Cell Therapies at ASH 2019 PR Newswire
Oct-28-19 08:20AM	Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment PR Newswire -29.36%
Oct-15-19 10:48AM	What Kind Of Investor Owns Most Of Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM)? Simply Wall St.
Sep-30-19 08:00AM	Actinium Announces Participation at the 2019 Cell & Gene Meeting on the Mesa PR Newswire
Sep-23-19 08:00AM	Actinium Announces Iomab-B Poster Selected for Honorable Distinction Award at the 2019 Society of Hematologic Oncology Annual Meeting from Nearly Four Hundred Abstracts PR Newswire
Sep-16-19 08:00AM	Actinium Pharmaceuticals to Present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment PR Newswire
Jul-23-19 08:00AM	Actinium Achieves Fifty Percent Enrollment in the Pivotal Phase 3 SIERRA Trial for Iomab-B PR Newswire +14.27%

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, developing Antibody Radiation-Conjugates (ARCs). The ARCs selectively kill patient's cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, CAR-T and other cell therapies or gene therapy to enable engraftment of these transplanted cells with minimal toxicities. It also offers Iomab-B (I-131 apamistamab), which is in a phase III study for Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The company is also developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with Astellas to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. The company was founded in 2000 and is based in New York, New York.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience